Global /United States /Healthcare /Drug Manufacturers - General /AARD

Aardvark Therapeutics, Inc.

AARD

• NASDAQ: AARD • Delayed

5.20USD -7%

As of 14 June 2026, Aardvark Therapeutics, Inc. has a market cap of $113.37M USD, ranking #24668 globally and #3826 in the United States. It ranks #2204 in the Healthcare sector, and #796 in the Drug Manufacturers - General industry.

Global Rank

24668

Country Rank

3826

Sector Rank

2204

Industry Rank

796

Key Stats

Market Cap

$113.37MUSD

Enterprise Value

$1.89MUSD

EBITDA (TTM)

-$62.69MUSD

Net Income (TTM)

-$57.59MUSD

PB Ratio

1.1

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Tien-Li Lee open_in_new

Employees

Founded

2017

IPO

13 Feb 2025

Website

aardvarktherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-7%	-6%	46%	-61%	-57%	-60%	-49%	-74%	-74%

News

AARD Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	AARD Aardvark Therapeutics Inc ISIN: US0029421007 Shares Out.: Shares Outstanding: 21.816M¹ Shares Float: 12.546M² TV: TradingView: NASDAQ: AARD SA: Stock Analysis: NASDAQ: AARD YF: Yahoo Finance: AARD GF: Google Finance: NASDAQ: AARD NQ: NASDAQ: AARD BA: Barron's: AARD MS: Morningstar: XNAS: AARD	5.20 USD	TV: TradingView: NASDAQ: AARD SA: Stock Analysis: NASDAQ: AARD YF: Yahoo Finance: AARD GF: Google Finance: NASDAQ: AARD NQ: NASDAQ: AARD BA: Barron's: AARD MS: Morningstar: XNAS: AARD

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 672K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 483K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 318K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 242K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 132K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 104K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 284K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 255K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 242K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 160K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 97K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 96K%	14.6	United Kingdom

chevron_leftBack